First Quarter 2008 - Issues in Hematology - ION Solutions

More documents

Recommendations

Info

oncologistics eye on ionEYE on IONGABRAIL CANCER CENTER RECOGNIZEDoncologistics volume 7, issue 1 - spring 2008 50Gabrail Cancer Center (GCC) in Canton, OH, with a satelliteoffi ce in Dover, OH, is a two-physician practice founded byNash Gabrail, M.D., in 1990. Multiple organizations haverecently recognized the center for demonstrating excellentpatient care.First, the practice has been nominated for the AmericanSociety of Clinical Oncology (ASCO) Foundation’sCommunity Oncology Research Award. GCC received theonly nomination from the Ohio/West Virginia Hematology/Oncology Society for the national award. This recognitionis based on the practice’s commitment to clinical research,and its contribution to the development, approval, andmarketing of several oncology drugs and supportivecare medications over the last 10 years. The winner ofthis award will be announced at this year’s annual ASCOmeeting in Chicago, IL.Also, Hematology & Oncology News & Issues (HONI)has recognized GCC with its Hematology and OncologyPractice Excellence (HOPE) award in the Clinical BestPractices category. Award panelists cited GCC’sinvolvement in clinical trials, development of FDA-basedSOPs, and utilization of EMR technology as some of thefactors contributing to its recognition.As the center continues to excel in the community,practice leaders consistently look for ways to improvecare. Over the past 18 months, the facility’s square footagehas increased by more than 400%, a second physicianwas added to the staff, a CT scanner was installed in theCanton facility, and the practice converted to an entirelypaperless model.GCC is a comprehensive cancer treatment facility wherepatients receive chemotherapy, obtain results quickly fromin-house lab and CT scanner, participate in clinical trials,and undergo procedures performed by the physicians allwithin the facility. GCC takes pride in the fact that all newpatients are seen within 48 hours, regardless of insurancestatus, and established patients are seen the same day.Through the use of cutting-edge technology, with a desireto stay on the forefront of clinical research, and withextreme dedication to their community, GCC continuesto provide the best treatments available for its patientsin a serene, home-like atmosphere. ❚
Note for printer: NOVARTIS 2PG INSERT TO GO HERE
Page 2 and 3: C O M I N G S O O NfromCEPHALON ONC
Page 4 and 5: © 2007 Bristol-Myers Squibb Compan
Page 6 and 7: industry insightHOSPIRA’S INCREAS
Page 8 and 9: industry insightWhat core competenc
Page 10 and 11: industry insightWhat differentiates
Page 12 and 13: XELODAEfficacy that makes a differe
Page 14 and 15: Brief summary of prescribing inform
Page 16 and 17: oncologistics volume 7, issue 1 - s
Page 20 and 21: IV IRON SUPPORTTHROUGHOUT CHEMOTHER
Page 22 and 23: established, and the test dose has
Page 24 and 25: eimbursement watchoncologistics vol
Page 26 and 27: eimbursement watch14236132158151241
Page 28 and 29: eimbursement watchon a coverage top
Page 30 and 31: drug updateTHESE STUDIESDEMONSTRATE
Page 32 and 33: drug updateoncologistics volume 7,
Page 34 and 35: POWER ANDPERFORMANCEVIDAZA hits MDS
Page 36 and 37: drug updateBased on recent findings
Page 38 and 39: drug updatehad been met. Median OS
Page 40 and 41: drug update(PDGF-ß), FLT-3, RET, a
Page 42 and 43: FURTHER PROGRESS IN THE TREATMENT O
Page 46 and 47: nurse’s forumOUTPATIENT MANAGEMEN
Page 48 and 49: nurse’s forumoncologistics volume
Page 52 and 53: Note for printer: NOVARTIS 2PG INSE
Page 55 and 56: “ ION provides me with a better v

First Quarter 2008 - Issues in Hematology - ION Solutions

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?